Leveraging more than 25 years of experience, Rob provides a wide range of corporate and securities legal services to innovative late-stage and public companies in the life sciences and technology industries. He represents issuers and underwriters in going public transactions, including IPOs, SPACs, reverse mergers, direct listings, as well as in follow-on offerings and private placements of equity and debt securities. Rob previously co-chaired Fenwick’s Public Company and Capital Markets practice.
Rob advises boards and management as an outside general counsel on day-to-day corporate and securities matters, including ’34 Act and public company reporting, corporate governance, and stock exchange rules and requirements
Rob also helps clients strategize capital raising efforts, navigate risk, and tell a story through filings and disclosures over the long term. He represented Loxo Oncology in its IPO, follow-on offerings and its $8 billion acquisition by Eli Lilly and DICE Therapeutics in its IPO, follow-on offerings and $2.4 billion sale to Eli Lily. He recently represented Day One Biopharmaceuticals, Morphic Holding and Prelude Therapeutics in their respective IPOs and subsequent follow-on offerings. Rob is committed to a company’s myriad legal needs through its full lifecycle.
Ranked as a top capital markets lawyer by Chambers USA, Chambers Global and Legal 500, and a preeminent life sciences practitioner by LMG Life Sciences, Rob is regularly sought after for his thought leadership. He is a lead author of the firm’s Technology and Life Sciences IPO Survey and co-chaired Practising Law Institute’s How to Prepare an Initial Public Offering annual program for several years.
Representative Initial Public Offerings and Other Going Public Transactions